Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 10/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548898 | 0.90 | RORC (0.39) | SMN1; SMN2HSD11B1P2RX7 | |
| SCHEMBL4505621 | 0.88 | NPY2R (0.36) | NPY2RMCHR1HSD11B1P2RX7 | |
| SCHEMBL4514917 | 0.88 | KMT2A (0.42) | EPHX2SMN1; SMN2 | |
| SCHEMBL4502644 | 0.87 | EPHX2 (0.42) | EPHX2NR1H4STSNPY2RGAA | |
| SCHEMBL4514423 | 0.86 | CHRM1 (0.43) | NPY2RHSD11B1 | |
| SCHEMBL4511065 | 0.85 | EPHX2 (0.36) | EPHX2SMN1; SMN2HSD11B1P2RX7 | |
| SCHEMBL4514431 | 0.84 | KMT2A (0.44) | NPY2RGAASMN1; SMN2MCHR1HSD11B1 | |
| SCHEMBL4507642 | 0.83 | EPHX2 (0.41) | EPHX2NR1H4GAA | |
| SCHEMBL13674531 | 0.83 | BMPR1B (0.38) | SMN1; SMN2MCHR1 | |
| SCHEMBL4528168 | 0.83 | BMPR1B (0.38) | SMN1; SMN2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | EPHX2 670/4885NR1H4 255/4885STS 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.